CTSB and BAG6 |
cathepsin B |
BCL2-associated athanogene 6 |
- Toll-Like Receptors Cascades
- Trafficking and processing of endosomal TLR
- Collagen formation
- Collagen degradation
- MHC class II antigen presentation
- Degradation of the extracellular matrix
- Assembly of collagen fibrils and other multimeric structures
- Adaptive Immune System
- Innate Immune System
|
|
- 2-Aminoethanimidic Acid
- 3-Amino-4-Oxybenzyl-2-Butanone
- 3-Methylphenylalanine
- N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline
- 2-Pyridinethiol
- Diphenylacetic Acid
- N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane
- N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-
- N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCINE
- BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE
- METHYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE
- N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ALANINE
- N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE
- N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE
|
|
|
|
MAPK1 and NTRK3 |
mitogen-activated protein kinase 1 |
neurotrophic tyrosine kinase, receptor, type 3 |
- phospho-PLA2 pathway
- Ca-dependent events
- Signaling by FGFR in disease
- Cellular Senescence
- ERKs are inactivated
- CREB phosphorylation through the activation of Ras
- Signaling by EGFRvIII in Cancer
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Fcgamma receptor (FCGR) dependent phagocytosis
- SHC-mediated signalling
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Regulation of actin dynamics for phagocytic cup formation
- TRIF-mediated TLR3/TLR4 signaling
- Senescence-Associated Secretory Phenotype (SASP)
- Signaling by VEGF
- Signalling to RAS
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Transmission across Chemical Synapses
- Axon guidance
- IRS-mediated signalling
- L1CAM interactions
- Oncogene Induced Senescence
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- RSK activation
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- NCAM signaling for neurite out-growth
- Signalling to p38 via RIT and RIN
- RAF/MAP kinase cascade
- Innate Immune System
- Signaling by Insulin receptor
- ERKs are inactivated
- Signal transduction by L1
- Insulin receptor signalling cascade
- PLC beta mediated events
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- G-protein mediated events
- Signaling by FGFR
- Thrombin signalling through proteinase activated receptors (PARs)
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- ERK/MAPK targets
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by GPCR
- Mitotic Prophase
- Golgi Cisternae Pericentriolar Stack Reorganization
- FCERI mediated MAPK activation
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- Opioid Signalling
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Signaling by Leptin
- Growth hormone receptor signaling
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Recycling pathway of L1
- M Phase
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- ERK activation
- Downstream signaling of activated FGFR
- Advanced glycosylation endproduct receptor signaling
- Post NMDA receptor activation events
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- Cellular response to heat stress
- Regulation of HSF1-mediated heat shock response
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell Cycle, Mitotic
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- Oxidative Stress Induced Senescence
- ERK2 activation
- Nuclear Events (kinase and transcription factor activation)
|
|
- Isoproterenol
- Arsenic trioxide
- Olomoucine
- Phosphonothreonine
- Purvalanol
- SB220025
- N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
- (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
- 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
- (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
|
|
|
|
PLA2G2A and BAG6 |
phospholipase A2, group IIA (platelets, synovial fluid) |
BCL2-associated athanogene 6 |
- Acyl chain remodelling of PG
- Acyl chain remodelling of PE
- Synthesis of PA
- Metabolism of lipids and lipoproteins
- Acyl chain remodelling of PI
- Phospholipid metabolism
- Glycerophospholipid biosynthesis
- Acyl chain remodelling of PC
- Acyl chain remodelling of PS
|
|
- Indomethacin
- Diclofenac
- Ginkgo biloba
- 1,4-Butanediol
- 1-{2-[2-(2-Methoxyethoxy)Ethoxy]Ethoxy}-4-(1,1,3,3-Tetramethylbutyl)Benzene
- N-Tridecanoic Acid
- [3-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Propyl-]-Phosphonic Acid
- 4-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Butyric Acid
- 1-Benzyl-5-Methoxy-2-Methyl-1h-Indol-3-Yl)-Acetic Acid
- 6-Phenyl-4(R)-(7-Phenyl-Heptanoylamino)-Hexanoic Acid
- Elaidoylamide
- 1-Octadecyl-2-Acetamido-2-Deoxy-Sn-Glycerol-3-Phosphoethylmethyl Sulfide
- (S)-5-(4-Benzyloxy-Phenyl)-4-(7-Phenyl-Heptanoylamino)-Pentanoic Acid
- Suramin
|
|
|
|
MAPK1 and HDAC4 |
mitogen-activated protein kinase 1 |
histone deacetylase 4 |
- phospho-PLA2 pathway
- Ca-dependent events
- Signaling by FGFR in disease
- Cellular Senescence
- ERKs are inactivated
- CREB phosphorylation through the activation of Ras
- Signaling by EGFRvIII in Cancer
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Fcgamma receptor (FCGR) dependent phagocytosis
- SHC-mediated signalling
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Regulation of actin dynamics for phagocytic cup formation
- TRIF-mediated TLR3/TLR4 signaling
- Senescence-Associated Secretory Phenotype (SASP)
- Signaling by VEGF
- Signalling to RAS
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Transmission across Chemical Synapses
- Axon guidance
- IRS-mediated signalling
- L1CAM interactions
- Oncogene Induced Senescence
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- RSK activation
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- NCAM signaling for neurite out-growth
- Signalling to p38 via RIT and RIN
- RAF/MAP kinase cascade
- Innate Immune System
- Signaling by Insulin receptor
- ERKs are inactivated
- Signal transduction by L1
- Insulin receptor signalling cascade
- PLC beta mediated events
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- G-protein mediated events
- Signaling by FGFR
- Thrombin signalling through proteinase activated receptors (PARs)
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- ERK/MAPK targets
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by GPCR
- Mitotic Prophase
- Golgi Cisternae Pericentriolar Stack Reorganization
- FCERI mediated MAPK activation
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- Opioid Signalling
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Signaling by Leptin
- Growth hormone receptor signaling
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Recycling pathway of L1
- M Phase
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- ERK activation
- Downstream signaling of activated FGFR
- Advanced glycosylation endproduct receptor signaling
- Post NMDA receptor activation events
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- Cellular response to heat stress
- Regulation of HSF1-mediated heat shock response
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell Cycle, Mitotic
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- Oxidative Stress Induced Senescence
- ERK2 activation
- Nuclear Events (kinase and transcription factor activation)
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by NOTCH1
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
|
- Isoproterenol
- Arsenic trioxide
- Olomoucine
- Phosphonothreonine
- Purvalanol
- SB220025
- N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
- (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
- 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
- (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
|
|
|
|
PARP1 and NFKB1 |
poly (ADP-ribose) polymerase 1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- TGFBR1 LBD Mutants in Cancer
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Loss of Function of TGFBR1 in Cancer
- Generic Transcription Pathway
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- SMAD4 MH2 Domain Mutants in Cancer
|
- Signaling by the B Cell Receptor (BCR)
- NF-kB is activated and signals survival
- Downstream TCR signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Cellular Senescence
- RIP-mediated NFkB activation via ZBP1
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- Downstream signaling events of B Cell Receptor (BCR)
- FCERI mediated NF-kB activation
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- ZBP1(DAI) mediated induction of type I IFNs
- p75NTR signals via NF-kB
- Transcriptional regulation of white adipocyte differentiation
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- Innate Immune System
- Regulated proteolysis of p75NTR
- Signalling by NGF
- TRIF-mediated TLR3/TLR4 signaling
- Cytosolic sensors of pathogen-associated DNA
- Senescence-Associated Secretory Phenotype (SASP)
- Cytokine Signaling in Immune system
- p75 NTR receptor-mediated signalling
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Signaling by Interleukins
- TCR signaling
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Interleukin-1 processing
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Activation of NF-kappaB in B cells
- Fc epsilon receptor (FCERI) signaling
- TRAF6 mediated NF-kB activation
- Interleukin-1 signaling
- Adaptive Immune System
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
- Carba-Nicotinamide-Adenine-Dinucleotide
- NU1025
- Nicotinamide
- 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
- 3-Methoxybenzamide
- 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
- 3,4-Dihydro-5-Methyl-Isoquinolinone
- 2-(3\'-Methoxyphenyl) Benzimidazole-4-Carboxamide
- 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
- (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium
- trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium
- 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
|
- Thalidomide
- Pranlukast
- Triflusal
|
|
|
EGFR and ANXA1 |
epidermal growth factor receptor |
annexin A1 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K/AKT activation
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by PDGF
- EGFR downregulation
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- L1CAM interactions
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signalling by NGF
- Signal transduction by L1
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Signaling by FGFR
- SHC1 events in EGFR signaling
- Constitutive Signaling by EGFRvIII
|
- G alpha (q) signalling events
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- Signaling by GPCR
- Class A/1 (Rhodopsin-like receptors)
- GPCR ligand binding
- Metabolic disorders of biological oxidation enzymes
- Formyl peptide receptors bind formyl peptides and many other ligands
- G alpha (q) signalling events
- GPCR downstream signaling
- Peptide ligand-binding receptors
- Gastrin-CREB signalling pathway via PKC and MAPK
- G alpha (i) signalling events
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Flavopiridol
- Vandetanib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
|
- Amcinonide
- Hydrocortisone
- Dexamethasone
|
|
|
PARP1 and TCF4 |
poly (ADP-ribose) polymerase 1 |
transcription factor 4 |
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- TGFBR1 LBD Mutants in Cancer
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Loss of Function of TGFBR1 in Cancer
- Generic Transcription Pathway
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- SMAD4 MH2 Domain Mutants in Cancer
|
- CDO in myogenesis
- Myogenesis
|
- Carba-Nicotinamide-Adenine-Dinucleotide
- NU1025
- Nicotinamide
- 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
- 3-Methoxybenzamide
- 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
- 3,4-Dihydro-5-Methyl-Isoquinolinone
- 2-(3\'-Methoxyphenyl) Benzimidazole-4-Carboxamide
- 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
- (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium
- trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium
- 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
|
|
|
|
EGFR and RIN2 |
epidermal growth factor receptor |
Ras and Rab interactor 2 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K/AKT activation
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by PDGF
- EGFR downregulation
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- L1CAM interactions
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signalling by NGF
- Signal transduction by L1
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Signaling by FGFR
- SHC1 events in EGFR signaling
- Constitutive Signaling by EGFRvIII
|
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Flavopiridol
- Vandetanib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
|
|
|
|
EGFR and ANKS1B |
epidermal growth factor receptor |
ankyrin repeat and sterile alpha motif domain containing 1B |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K/AKT activation
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by PDGF
- EGFR downregulation
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- L1CAM interactions
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signalling by NGF
- Signal transduction by L1
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Signaling by FGFR
- SHC1 events in EGFR signaling
- Constitutive Signaling by EGFRvIII
|
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Flavopiridol
- Vandetanib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
|
|
|
|
RXRA and NFKB1 |
retinoid X receptor, alpha |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
- Bile acid and bile salt metabolism
- Metabolism of lipids and lipoproteins
- Nuclear Receptor transcription pathway
- Metabolic disorders of biological oxidation enzymes
- Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
- Generic Transcription Pathway
- Endogenous sterols
- Synthesis of bile acids and bile salts
- Orphan transporters
- Defective FMO3 causes Trimethylaminuria (TMAU)
- Signaling by Retinoic Acid
- Recycling of bile acids and salts
- Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
- Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
- Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
- Regulation of pyruvate dehydrogenase (PDH) complex
- Pyruvate metabolism
- Synthesis of bile acids and bile salts via 27-hydroxycholesterol
- Defective MAOA causes Brunner syndrome (BRUNS)
- Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
- Activation of gene expression by SREBF (SREBP)
- The citric acid (TCA) cycle and respiratory electron transport
- Transcriptional activation of mitochondrial biogenesis
- PPARA activates gene expression
- Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
- Organelle biogenesis and maintenance
- Import of palmitoyl-CoA into the mitochondrial matrix
- Pyruvate metabolism and Citric Acid (TCA) cycle
- Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
- Phase 1 - Functionalization of compounds
- RORA activates circadian gene expression
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
- Cytochrome P450 - arranged by substrate type
- Transcriptional regulation of white adipocyte differentiation
- Biological oxidations
- Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
- Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
- Fatty acid, triacylglycerol, and ketone body metabolism
- Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
- Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
- REV-ERBA represses gene expression
- Defective CYP1B1 causes Glaucoma
- Mitochondrial biogenesis
- Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
- Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
- Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
- Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
- Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- Signaling by the B Cell Receptor (BCR)
- NF-kB is activated and signals survival
- Downstream TCR signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Cellular Senescence
- RIP-mediated NFkB activation via ZBP1
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- Downstream signaling events of B Cell Receptor (BCR)
- FCERI mediated NF-kB activation
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- ZBP1(DAI) mediated induction of type I IFNs
- p75NTR signals via NF-kB
- Transcriptional regulation of white adipocyte differentiation
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- Innate Immune System
- Regulated proteolysis of p75NTR
- Signalling by NGF
- TRIF-mediated TLR3/TLR4 signaling
- Cytosolic sensors of pathogen-associated DNA
- Senescence-Associated Secretory Phenotype (SASP)
- Cytokine Signaling in Immune system
- p75 NTR receptor-mediated signalling
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Signaling by Interleukins
- TCR signaling
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Interleukin-1 processing
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Activation of NF-kappaB in B cells
- Fc epsilon receptor (FCERI) signaling
- TRAF6 mediated NF-kB activation
- Interleukin-1 signaling
- Adaptive Immune System
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
- Adapalene
- Bexarotene
- Acitretin
- Alitretinoin
- Etodolac
- Etretinate
- (5BETA)-PREGNANE-3,20-DIONE
- 2-chloro-5-nitro-N-phenylbenzamide
- 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- tributylstannanyl
|
- Thalidomide
- Pranlukast
- Triflusal
|
|
|
RXRA and ARNTL |
retinoid X receptor, alpha |
aryl hydrocarbon receptor nuclear translocator-like |
- Bile acid and bile salt metabolism
- Metabolism of lipids and lipoproteins
- Nuclear Receptor transcription pathway
- Metabolic disorders of biological oxidation enzymes
- Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
- Generic Transcription Pathway
- Endogenous sterols
- Synthesis of bile acids and bile salts
- Orphan transporters
- Defective FMO3 causes Trimethylaminuria (TMAU)
- Signaling by Retinoic Acid
- Recycling of bile acids and salts
- Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
- Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
- Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
- Regulation of pyruvate dehydrogenase (PDH) complex
- Pyruvate metabolism
- Synthesis of bile acids and bile salts via 27-hydroxycholesterol
- Defective MAOA causes Brunner syndrome (BRUNS)
- Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
- Activation of gene expression by SREBF (SREBP)
- The citric acid (TCA) cycle and respiratory electron transport
- Transcriptional activation of mitochondrial biogenesis
- PPARA activates gene expression
- Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
- Organelle biogenesis and maintenance
- Import of palmitoyl-CoA into the mitochondrial matrix
- Pyruvate metabolism and Citric Acid (TCA) cycle
- Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
- Phase 1 - Functionalization of compounds
- RORA activates circadian gene expression
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
- Cytochrome P450 - arranged by substrate type
- Transcriptional regulation of white adipocyte differentiation
- Biological oxidations
- Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
- Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
- Fatty acid, triacylglycerol, and ketone body metabolism
- Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
- Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
- REV-ERBA represses gene expression
- Defective CYP1B1 causes Glaucoma
- Mitochondrial biogenesis
- Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
- Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
- Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
- Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
- Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
- Adapalene
- Bexarotene
- Acitretin
- Alitretinoin
- Etodolac
- Etretinate
- (5BETA)-PREGNANE-3,20-DIONE
- 2-chloro-5-nitro-N-phenylbenzamide
- 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- tributylstannanyl
|
|
|
|
RXRA and HDAC4 |
retinoid X receptor, alpha |
histone deacetylase 4 |
- Bile acid and bile salt metabolism
- Metabolism of lipids and lipoproteins
- Nuclear Receptor transcription pathway
- Metabolic disorders of biological oxidation enzymes
- Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
- Generic Transcription Pathway
- Endogenous sterols
- Synthesis of bile acids and bile salts
- Orphan transporters
- Defective FMO3 causes Trimethylaminuria (TMAU)
- Signaling by Retinoic Acid
- Recycling of bile acids and salts
- Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
- Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
- Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
- Regulation of pyruvate dehydrogenase (PDH) complex
- Pyruvate metabolism
- Synthesis of bile acids and bile salts via 27-hydroxycholesterol
- Defective MAOA causes Brunner syndrome (BRUNS)
- Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
- Activation of gene expression by SREBF (SREBP)
- The citric acid (TCA) cycle and respiratory electron transport
- Transcriptional activation of mitochondrial biogenesis
- PPARA activates gene expression
- Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
- Organelle biogenesis and maintenance
- Import of palmitoyl-CoA into the mitochondrial matrix
- Pyruvate metabolism and Citric Acid (TCA) cycle
- Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
- Phase 1 - Functionalization of compounds
- RORA activates circadian gene expression
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
- Cytochrome P450 - arranged by substrate type
- Transcriptional regulation of white adipocyte differentiation
- Biological oxidations
- Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
- Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
- Fatty acid, triacylglycerol, and ketone body metabolism
- Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
- Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
- REV-ERBA represses gene expression
- Defective CYP1B1 causes Glaucoma
- Mitochondrial biogenesis
- Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
- Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
- Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
- Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
- Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by NOTCH1
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
|
- Adapalene
- Bexarotene
- Acitretin
- Alitretinoin
- Etodolac
- Etretinate
- (5BETA)-PREGNANE-3,20-DIONE
- 2-chloro-5-nitro-N-phenylbenzamide
- 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- tributylstannanyl
|
|
|
|
KIT and CSF2RA |
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog |
colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Regulation of KIT signaling
- PI3K/AKT activation
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signaling by PDGF
- Signalling by NGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by ERBB4
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- Signaling by GPCR
- G-protein beta:gamma signalling
- Cytokine Signaling in Immune system
- GPCR downstream signaling
- Signaling by Interleukins
- Interleukin receptor SHC signaling
- G beta:gamma signalling through PI3Kgamma
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
|
- Sorafenib
- Imatinib
- Dasatinib
- Sunitinib
- Phosphonotyrosine
- Adenosine-5\'-Diphosphate
- Nilotinib
- Pazopanib
- Regorafenib
- Ponatinib
|
|
|
|
CASP3 and TRAF3 |
caspase 3, apoptosis-related cysteine peptidase |
TNF receptor-associated factor 3 |
- SMAC binds to IAPs
- SMAC-mediated dissociation of IAP:caspase complexes
- SMAC-mediated apoptotic response
- Cytochrome c-mediated apoptotic response
- Caspase-mediated cleavage of cytoskeletal proteins
- Degradation of the extracellular matrix
- Role of DCC in regulating apoptosis
- Activation of caspases through apoptosome-mediated cleavage
- Activation of DNA fragmentation factor
- Apoptotic factor-mediated response
- Programmed Cell Death
- Intrinsic Pathway for Apoptosis
- Signalling by NGF
- Apoptotic cleavage of cellular proteins
- Cell death signalling via NRAGE, NRIF and NADE
- Apoptotic execution phase
- p75 NTR receptor-mediated signalling
- Stimulation of the cell death response by PAK-2p34
- Apoptotic cleavage of cell adhesion proteins
- Signaling by Hippo
- Apoptosis induced DNA fragmentation
- Extrinsic Pathway
- NADE modulates death signalling
|
- Activated TLR4 signalling
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- TRAF3-dependent IRF activation pathway
- Toll-Like Receptors Cascades
- Negative regulators of RIG-I/MDA5 signaling
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- MyD88-independent cascade
- Innate Immune System
- Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
|
- Minocycline
- 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
- 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
- methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
- 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
- [N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID
- 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
- (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- N-[3-(2-fluoroethoxy)phenyl]-N\'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
|
|
|
|
PLG and ENO1 |
plasminogen |
enolase 1, (alpha) |
- Signaling by PDGF
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- Activation of Matrix Metalloproteinases
- Dissolution of Fibrin Clot
- Platelet degranulation
- Degradation of the extracellular matrix
- Response to elevated platelet cytosolic Ca2+
- Platelet activation, signaling and aggregation
- Orphan transporters
|
- Gluconeogenesis
- Glucose metabolism
- Myoclonic epilepsy of Lafora
- Glycogen storage diseases
- Glycolysis
- Metabolism of carbohydrates
|
- Alteplase
- Urokinase
- Reteplase
- Anistreplase
- Tenecteplase
- Streptokinase
- Tranexamic Acid
- Aminocaproic Acid
- Bicine
- Aprotinin
|
|
|
|
VEGFA and GPC1 |
vascular endothelial growth factor A |
glypican 1 |
- VEGF binds to VEGFR leading to receptor dimerization
- Cellular response to hypoxia
- VEGF ligand-receptor interactions
- Regulation of Hypoxia-inducible Factor (HIF) by oxygen
- Signaling by VEGF
- Response to elevated platelet cytosolic Ca2+
- Platelet degranulation
- Platelet activation, signaling and aggregation
- Regulation of gene expression by Hypoxia-inducible Factor
|
- MPS IIIB - Sanfilippo syndrome B
- Diseases of glycosylation
- Defective B4GALT7 causes EDS, progeroid type
- Axon guidance
- Heparan sulfate/heparin (HS-GAG) metabolism
- MPS I - Hurler syndrome
- MPS IX - Natowicz syndrome
- Chondroitin sulfate/dermatan sulfate metabolism
- Defective SLC26A2 causes chondrodysplasias
- Glycosaminoglycan metabolism
- Inactivation of Cdc42 and Rac
- Defective CHST14 causes EDS, musculocontractural type
- Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
- Defective PAPSS2 causes SEMD-PA
- Activation of Rac
- MPS IIIA - Sanfilippo syndrome A
- Myoclonic epilepsy of Lafora
- Defective CHST6 causes MCDC1
- Glycogen storage diseases
- MPS IIID - Sanfilippo syndrome D
- A tetrasaccharide linker sequence is required for GAG synthesis
- MPS IIIC - Sanfilippo syndrome C
- Retinoid metabolism and transport
- Role of Abl in Robo-Slit signaling
- Diseases associated with glycosaminoglycan metabolism
- Mucopolysaccharidoses
- Defective EXT2 causes exostoses 2
- MPS II - Hunter syndrome
- Defective B3GAT3 causes JDSSDHD
- Defective CHST3 causes SEDCJD
- Defective EXT1 causes exostoses 1, TRPS2 and CHDS
- Diseases associated with visual transduction
- MPS IV - Morquio syndrome A
- Visual phototransduction
- MPS IV - Morquio syndrome B
- Defective CHSY1 causes TPBS
- MPS VII - Sly syndrome
- Metabolism of carbohydrates
- Signaling by Robo receptor
- HS-GAG biosynthesis
- HS-GAG degradation
- MPS VI - Maroteaux-Lamy syndrome
|
- Bevacizumab
- Minocycline
- Gliclazide
- Carvedilol
- Ranibizumab
- Pyroglutamic Acid
- Tris(Hydroxymethyl)Aminomethane
- Vandetanib
- Dalteparin
- Aflibercept
|
|
|
|
KIT and PTPRU |
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog |
protein tyrosine phosphatase, receptor type, U |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Regulation of KIT signaling
- PI3K/AKT activation
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signaling by PDGF
- Signalling by NGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by ERBB4
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
|
- Sorafenib
- Imatinib
- Dasatinib
- Sunitinib
- Phosphonotyrosine
- Adenosine-5\'-Diphosphate
- Nilotinib
- Pazopanib
- Regorafenib
- Ponatinib
|
|
|
|
PPARD and HDAC4 |
peroxisome proliferator-activated receptor delta |
histone deacetylase 4 |
- Regulation of pyruvate dehydrogenase (PDH) complex
- Pyruvate metabolism
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Signaling by Retinoic Acid
- Import of palmitoyl-CoA into the mitochondrial matrix
- Pyruvate metabolism and Citric Acid (TCA) cycle
- Nuclear Receptor transcription pathway
- The citric acid (TCA) cycle and respiratory electron transport
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by NOTCH1
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
|
- Icosapent
- Treprostinil
- Sulindac
- Bezafibrate
- Heptyl-Beta-D-Glucopyranoside
- (11E)-OCTADEC-11-ENOIC ACID
- (2S)-2-{3-[({[2-fluoro-4-(trifluoromethyl)phenyl]carbonyl}amino)methyl]-4-methoxybenzyl}butanoic acid
- 2-({[3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- {4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy}acetic acid
|
|
|
|
VEGFA and NRP1 |
vascular endothelial growth factor A |
neuropilin 1 |
- VEGF binds to VEGFR leading to receptor dimerization
- Cellular response to hypoxia
- VEGF ligand-receptor interactions
- Regulation of Hypoxia-inducible Factor (HIF) by oxygen
- Signaling by VEGF
- Response to elevated platelet cytosolic Ca2+
- Platelet degranulation
- Platelet activation, signaling and aggregation
- Regulation of gene expression by Hypoxia-inducible Factor
|
- Signal transduction by L1
- CHL1 interactions
- Axon guidance
- Semaphorin interactions
- Signaling by VEGF
- Sema3A PAK dependent Axon repulsion
- Neurophilin interactions with VEGF and VEGFR
- L1CAM interactions
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- CRMPs in Sema3A signaling
|
- Bevacizumab
- Minocycline
- Gliclazide
- Carvedilol
- Ranibizumab
- Pyroglutamic Acid
- Tris(Hydroxymethyl)Aminomethane
- Vandetanib
- Dalteparin
- Aflibercept
|
|
|
|
FGF1 and NRP1 |
fibroblast growth factor 1 (acidic) |
neuropilin 1 |
- Signaling by the B Cell Receptor (BCR)
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- SHC-mediated cascade
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Signaling by FGFR2 mutants
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- Signaling by activated point mutants of FGFR1
- Signaling by FGFR1 mutants
- PI3K Cascade
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- Activated point mutants of FGFR2
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- FGFR4 ligand binding and activation
- Signaling by EGFR
- Signaling by FGFR3 mutants
- Downstream signal transduction
- Signaling by activated point mutants of FGFR3
- Fc epsilon receptor (FCERI) signaling
- Signaling by FGFR mutants
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- PI3K events in ERBB2 signaling
- FGFR1b ligand binding and activation
- Downstream signaling of activated FGFR
- FGFR3b ligand binding and activation
- FGFR3c ligand binding and activation
- FGFR1c ligand binding and activation
- FGFR2c ligand binding and activation
- FGFR ligand binding and activation
- FGFR2b ligand binding and activation
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- FGFR3 ligand binding and activation
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- FRS2-mediated cascade
- FGFR2 ligand binding and activation
- IRS-mediated signalling
- FGFR1 ligand binding and activation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PI3K Cascade
|
- Signal transduction by L1
- CHL1 interactions
- Axon guidance
- Semaphorin interactions
- Signaling by VEGF
- Sema3A PAK dependent Axon repulsion
- Neurophilin interactions with VEGF and VEGFR
- L1CAM interactions
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- CRMPs in Sema3A signaling
|
- Pentosan Polysulfate
- Amlexanox
- Sucrose Octasulfate
- Formic Acid
- O2-Sulfo-Glucuronic Acid
- N,O6-Disulfo-Glucosamine
- Naphthalene Trisulfonate
- Pazopanib
- 5-AMINO-NAPHTALENE-2-MONOSULFONATE
|
|
|
|